SCHEMBL6626142

SCHEMBL6626142

CC(=O)N(c1ccccc1)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.46
MEN1 O00255 4/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 4/20 0.44
TSHR P16473 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
GLA P06280 1/20 0.41
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
ALOX15 P16050 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
APAF1 O14727 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28133300 0.85 KMT2A (0.44) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL7034982 0.84 KMT2A (0.47) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL10959895 0.84 NPSR1 (0.50) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL27411784 0.83 KMT2A (0.43) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL7827701 0.81 NPSR1 (0.41) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL11437979 0.81 KMT2A (0.44) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL9435677 0.81 KMT2A (0.45) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL2410084 0.81 NPSR1 (0.41) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL11882082 0.79 NPSR1 (0.45) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL19570751 0.79 NPSR1 (0.61) KMT2AMEN1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
US-20240226104-A1 PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-07-11 US disclosed
CN-113912529-B Method for synthesizing indole compounds by catalyzing N-aryl amide compounds and vinylene carbonate with ruthenium 成都大学 2023-07-25 CN disclosed
CN-113912529-A Method for synthesizing indole compound by catalyzing N-aryl amide compound and vinylene carbonate with ruthenium 成都大学 2022-01-11 CN disclosed
WO-1995024395-A1 QUINOLINE DERIVATIVES AS IMMUNOMODULATORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226104-A1 PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF PI4KA, PIK3CA, PI4KB KMT2A 2967/4885MEN1 3531/4885CYP3A4 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.